Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.30 +2.2%	$2.51	$2.03 ▼ $4.00	$233.47M	1.57	301,418 shs	55,079 shs
ALVO Alvotech	$3.54 +3.7%	$3.57	$2.94 ▼ $9.94	$1.07B	0.19	598,671 shs	272,007 shs
ANRO Alto Neuroscience	$26.90 +3.8%	$23.20	$2.72 ▼ $28.85	$944.27M	1.04	364,336 shs	150,313 shs
JANX Janux Therapeutics	$16.23 +1.1%	$14.70	$12.12 ▼ $35.34	$990.93M	2.52	1.19 million shs	250,003 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	+2.27%	-8.16%	-6.25%	-21.60%	+8.70%
ALVO Alvotech	-1.45%	+0.89%	-13.01%	-2.85%	-60.49%
ANRO Alto Neuroscience	-5.60%	-7.46%	+14.65%	+1.74%	+835.29%
JANX Janux Therapeutics	-1.29%	-0.56%	+12.87%	+3.82%	-39.20%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.30 +2.2%	$2.51	$2.03 ▼ $4.00	$233.47M	1.57	301,418 shs	55,079 shs
ALVO Alvotech	$3.54 +3.7%	$3.57	$2.94 ▼ $9.94	$1.07B	0.19	598,671 shs	272,007 shs
ANRO Alto Neuroscience	$26.90 +3.8%	$23.20	$2.72 ▼ $28.85	$944.27M	1.04	364,336 shs	150,313 shs
JANX Janux Therapeutics	$16.23 +1.1%	$14.70	$12.12 ▼ $35.34	$990.93M	2.52	1.19 million shs	250,003 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	+2.27%	-8.16%	-6.25%	-21.60%	+8.70%
ALVO Alvotech	-1.45%	+0.89%	-13.01%	-2.85%	-60.49%
ANRO Alto Neuroscience	-5.60%	-7.46%	+14.65%	+1.74%	+835.29%
JANX Janux Therapeutics	-1.29%	-0.56%	+12.87%	+3.82%	-39.20%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	2.40	Hold	$7.50	226.09% Upside
ALVO Alvotech	2.00	Hold	$7.60	114.99% Upside
ANRO Alto Neuroscience	2.70	Moderate Buy	$35.25	31.07% Upside
JANX Janux Therapeutics	2.50	Moderate Buy	$38.08	134.63% Upside

Current Analyst Ratings Breakdown

Latest ACIU, ALVO, JANX, and ANRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2026	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/25/2026	JANX Janux Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$80.00 ➝ $26.00
6/17/2026	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/9/2026	ALVO Alvotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/27/2026	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
5/22/2026	ANRO Alto Neuroscience	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
5/18/2026	ANRO Alto Neuroscience	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$38.00 ➝ $36.00
5/14/2026	ANRO Alto Neuroscience	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$21.00 ➝ $24.00
5/11/2026	ALVO Alvotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/11/2026	JANX Janux Therapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$22.00
5/11/2026	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00

(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$3.70M	63.23	N/A	N/A	$0.54 per share	4.26
ALVO Alvotech	$588.90M	1.81	$0.22 per share	15.88	($0.94) per share	-3.76
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$4.87 per share	N/A
JANX Janux Therapeutics	$10M	98.98	N/A	N/A	$15.91 per share	1.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$85.03M	-$0.82	N/A	13.53	N/A	-1,788.02%	-125.26%	-40.85%	8/4/2026 (Estimated)
ALVO Alvotech	$27.92M	-$0.25	N/A	11.05	N/A	-14.36%	-11.92%	-7.59%	8/12/2026 (Estimated)
ANRO Alto Neuroscience	-$63.24M	-$2.42	N/A	N/A	N/A	N/A	-47.22%	-38.81%	8/12/2026 (Estimated)
JANX Janux Therapeutics	-$113.62M	-$1.84	N/A	N/A	N/A	N/A	-12.93%	-12.23%	8/6/2026 (Estimated)

Latest ACIU, ALVO, JANX, and ANRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ALVO Alvotech	-$0.04	N/A	N/A	N/A	$111.50 million	N/A
8/12/2026	Q2 2026	ANRO Alto Neuroscience	-$0.71	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	JANX Janux Therapeutics	-$0.26	N/A	N/A	N/A	$19.08 million	N/A
8/4/2026	Q2 2026	ACIU AC Immune	$0.0981	N/A	N/A	N/A	$34.05 million	N/A
5/13/2026	Q1 2026	ANRO Alto Neuroscience	-$0.56	-$0.80	-$0.24	-$0.80	N/A	N/A
5/7/2026	Q1 2026	ALVO Alvotech	-$0.07	-$0.09	-$0.02	N/A	$112.39 million	$105.90 million
5/7/2026	Q1 2026	JANX Janux Therapeutics	-$0.5202	-$0.39	+$0.1302	-$0.39	$4.36 million	$3.73 million
4/30/2026	Q1 2026	ACIU AC Immune	-$0.20	-$0.19	+$0.01	-$0.19	$0.33 million	$1.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	0.11	0.87	1.02
ALVO Alvotech	N/A	1.76	0.88
ANRO Alto Neuroscience	0.07	20.52	20.52
JANX Janux Therapeutics	N/A	17.01	17.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
ALVO Alvotech	N/A
ANRO Alto Neuroscience	N/A
JANX Janux Therapeutics	75.39%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
ALVO Alvotech	N/A
ANRO Alto Neuroscience	11.25%
JANX Janux Therapeutics	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	101.77 million	97.09 million	Optionable
ALVO Alvotech	1,460	301.81 million	N/A	Not Optionable
ANRO Alto Neuroscience	N/A	35.09 million	31.15 million	N/A
JANX Janux Therapeutics	30	60.98 million	56.17 million	Optionable

ACIU, ALVO, JANX, and ANRO Headlines

Recent News About These Companies

BML Capital Management LLC Purchases Shares of 154,961 Janux Therapeutics, Inc. $JANX

July 17, 2026 | marketbeat.com

Janux Therapeutics Insider Trading Activity | NASDAQ:JANX | Benzinga

July 15, 2026 | benzinga.com

Y Intercept Hong Kong Ltd Takes Position in Janux Therapeutics, Inc. $JANX

July 9, 2026 | marketbeat.com

Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential?

June 30, 2026 | finance.yahoo.com

Janux Therapeutics Inc Ordinary Shares JANX

June 28, 2026 | morningstar.comM

5 Most Promising Cancer Stocks According to Wall Street Analysts

June 28, 2026 | insidermonkey.com

Janux Therapeutics Announces Departure of Chief Medical Officer

June 23, 2026 | tipranks.com

Janux Therapeutics Reports Results of 2026 Annual Meeting

June 12, 2026 | tipranks.com

Janux Therapeutics (NASDAQ:JANX) Insider Janeen Noel Doyle Sells 4,059 Shares

June 5, 2026 | insidertrades.com

Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know

May 28, 2026 | zacks.com

Here's Why You Should Add JANX Stock to Your Portfolio Now

May 26, 2026 | zacks.com

Janux Therapeutics (JANX) price target decreased by 14.60% to 42.12

May 14, 2026 | msn.com

Wedbush Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)

May 14, 2026 | theglobeandmail.com

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates

May 7, 2026 | zacks.com

How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%

May 7, 2026 | zacks.com

Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value

May 4, 2026 | seekingalpha.com

Janux Therapeutics halts early stage cancer program in 'prudent' move

April 28, 2026 | msn.com

JANX stock edges up after hours after discontinuing cancer program in favor of remaining pipeline

April 28, 2026 | msn.com

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

April 28, 2026 | finance.yahoo.com

First Patient Dosed in JANX014 Trial in Metastatic CRPC

April 22, 2026 | targetedonc.comT

Barclays downgrades Janux Therapeutics (JANX)

April 20, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU, ALVO, JANX, and ANRO Company Descriptions

AC Immune NASDAQ:ACIU

$2.30 +0.05 (+2.22%)

As of 01:50 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Alvotech NASDAQ:ALVO

$3.54 +0.13 (+3.67%)

As of 01:49 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Alto Neuroscience NYSE:ANRO

$26.90 +1.00 (+3.84%)

As of 01:50 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Janux Therapeutics NASDAQ:JANX

$16.23 +0.18 (+1.13%)

As of 01:50 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACIU, ALVO, JANX, and ANRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACIU, ALVO, JANX, and ANRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACIU, ALVO, JANX, and ANRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU, ALVO, JANX, and ANRO Company Descriptions

AC Immune NASDAQ:ACIU

Alvotech NASDAQ:ALVO

Alto Neuroscience NYSE:ANRO

Janux Therapeutics NASDAQ:JANX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACIU, ALVO, JANX, and ANRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACIU, ALVO, JANX, and ANRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACIU, ALVO, JANX, and ANRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU, ALVO, JANX, and ANRO Company Descriptions

AC Immune NASDAQ:ACIU

Alvotech NASDAQ:ALVO

Alto Neuroscience NYSE:ANRO

Janux Therapeutics NASDAQ:JANX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools